Quickly determine therapeutic candidates that modulate regulatory T cells in high throughput, leveraging Horizon's comprehensive knowledge in screening. We will obtain in-vitro data from multiple donors of your small molecules or biologics to move your project forward.
|Service description||Number of suitable compounds||Catalog Number|
|Standard iTreg Polarization Assay - Mini||1 to 5||IMM04-01|
|Standard iTreg Polarization Assay - Midi||6 to 11||IMM04-02|
|Standard iTreg Polarization Assay - Maxi||12 to 17||IMM04-03|
Standard iTreg polarization assay readouts and cloud-based data report
- T cell viability
- T cell phenotyping for:CD25, CD127 and Foxp3
- 9 points compound dose response (8 dilutions + vehicle)
- Data points set of quadruplicates
- 3-fold dilution range
- All plotted data and raw data files are provided
- Table of EC50s
- Quality control data for cell isolation cells and internal assay controls
Representative data of the iTreg polarization assay
A) Optimization of naïve CD4+ T cell polarizing condition in the 384-well plate format. Data represent quadruplicate technical repeats cultured from three donors. B) Drug-modulated iTreg polarization by GSK1059615 during polarization reduced the expression of Foxp3. Flow cytometry data represent naïve T cells cultured from 3 donors in quadruplicate replicates. C) Viability assessment of cells treated with GSK1059615 in the iTreg polarization assay.
Contact us to discuss your project using the form provided and one of the team will be in touch.
Answer questions in biologically relevant primary immune cell types. Leveraging our expertise in screening and receive robust data from high-throughput assays.
ImmuSignature™ assays: Compound screening in primary immune cells
Rapid in-vitro assessment of therapeutic candidates for immune applications from oncology to autoimmunity
Read Horizon's immunology blog
Get the latest insights about the drug discovery tools in the immunology field, curated by Horizon's scientists.